BioPharma Resources

Drug Trial Radar · NCT05037760

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Dec 16, 2021

Primary completion

Feb 28, 2028

Study completion Feb 28, 2030

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to learn how safe elritercept is and how well it is tolerated when taken alone and in combination with the JAK inhibitor, ruxolitinib. Other aims are to learn about the effects of elritercept on the signs and symptoms of MF when taken with or without ruxolitinib and to learn how elritercept affects the body, how the body processes elritercept, and the effects of elritercept on anemia when taken with or without ruxolitinib The study will also check on how safe elritercept is and how well it is tolerated.

Conditions

  • Myelofibrosis

Interventions

  • ElriterceptDrug

    Elritercept SC injection.

  • RuxolitinibDrug

    Ruxolitinib tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants with Adverse Events (AEs), Dose Limiting Toxicities (DLTs), Severe Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From signing of the informed consent form (ICF) through 30 days after the last dose of study drug (approximately 8 years)
  2. Part 2 and Long-Term Extension: Number of Participants with Adverse Events (AEs), Severe AEs and SAEsTime frame: From signing of the ICF through 30 days after the last dose of study drug, (approximately 8 years)

Locations

46 sites in 7 countries. Site status is shown where the registry gives one.

  • Concord Hospital

    Concord, New South Wales, Australia · Recruiting

  • The Tweed Hospital

    Tweed Heads, New South Wales, Australia · Recruiting

  • Flinders Medical Centre

    Woodville South, South Australia, Australia · Recruiting

  • St. Vincents Hospital Melbourne

    Fitzroy, Victoria, Australia · Recruiting

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Ballarat Oncology & Haematology Service

    Wendouree, Victoria, Australia · Recruiting

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Brazil · Recruiting

  • IMV-Pesquisa Cardiologica Sociedade Simples

    Porto Alegre, Brazil · Recruiting

  • Albert Einstein Sociedade Beneficente Israelita Brasiliera

    São Paulo, Brazil · Recruiting

  • Hospital Beneficencia Portuguesa de Sao Paulo

    São Paulo, Brazil · Recruiting

  • Hospital Das Clinicas Da Faculdade de Medicina Da U S P

    São Paulo, Brazil · Recruiting

  • Instituto de Ensino e Pesquisas Sao Lucas

    São Paulo, Brazil · Recruiting

  • CHU Amiens - Hopital Sud

    Amiens, France · Completed

  • Hopital Morvan

    Brest, France · Completed

  • Hopital Prive Sevigne

    Cesson-Sévigné, France · Completed

  • Centre Hospitalier Lyon Sud

    Lyon, France · Recruiting

  • Institut de Cancerologie du Gard

    Nîmes, France · Recruiting

  • Hopital de la Source - CHR Orleans

    Orléans, France · Completed

  • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari

    Bari, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi

    Bologna, Italy · Recruiting

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

    Brescia, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy · Recruiting

  • Ospedale Policlinico San Martino

    Genova, Italy · Recruiting

  • ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center

    Milan, Italy · Recruiting

  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico

    Milan, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Milan, Italy · Completed

  • Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia

    Reggio Emilia, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Policlinico Umberto I

    Roma, Italy · Recruiting

  • Azienda Socio Sanitaria Territoriale Sette Laghi

    Varese, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, Italy · Recruiting

  • Gachon University Gil Medical Center

    Incheon, South Korea · Completed

  • Samsung Medical Center

    Seoul, South Korea · Completed

  • Seoul St. Marys Hospital, The Catholic University of Korea

    Seoul, South Korea · Recruiting

  • Soonchunhyang University Seoul Hospital

    Seoul, South Korea · Recruiting

  • ICO Badalona - Hospital Universitari Germans Trias i Pujol

    Badalona, Spain · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Hospital Universitario La Princesa

    Madrid, Spain · Recruiting

  • Hospital Universitario de Salamanca

    Salamanca, Spain · Recruiting

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain · Recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.